AU2015382376B2 - Cenicriviroc for the treatment of fibrosis - Google Patents

Cenicriviroc for the treatment of fibrosis Download PDF

Info

Publication number
AU2015382376B2
AU2015382376B2 AU2015382376A AU2015382376A AU2015382376B2 AU 2015382376 B2 AU2015382376 B2 AU 2015382376B2 AU 2015382376 A AU2015382376 A AU 2015382376A AU 2015382376 A AU2015382376 A AU 2015382376A AU 2015382376 B2 AU2015382376 B2 AU 2015382376B2
Authority
AU
Australia
Prior art keywords
cvc
liver
cenicriviroc
treatment
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2015382376A
Other languages
English (en)
Other versions
AU2015382376A1 (en
Inventor
Eric Lefebvre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tobira Therapeutics Inc
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of AU2015382376A1 publication Critical patent/AU2015382376A1/en
Application granted granted Critical
Publication of AU2015382376B2 publication Critical patent/AU2015382376B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015382376A 2015-02-10 2015-09-22 Cenicriviroc for the treatment of fibrosis Expired - Fee Related AU2015382376B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562114304P 2015-02-10 2015-02-10
US62/114,304 2015-02-10
PCT/US2015/051467 WO2016130179A1 (en) 2015-02-10 2015-09-22 Cenicriviroc for the treatment of fibrosis

Publications (2)

Publication Number Publication Date
AU2015382376A1 AU2015382376A1 (en) 2017-08-17
AU2015382376B2 true AU2015382376B2 (en) 2021-07-01

Family

ID=56614560

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015382376A Expired - Fee Related AU2015382376B2 (en) 2015-02-10 2015-09-22 Cenicriviroc for the treatment of fibrosis

Country Status (15)

Country Link
US (3) US20180110754A1 (cg-RX-API-DMAC10.html)
EP (1) EP3256124B1 (cg-RX-API-DMAC10.html)
JP (2) JP6676660B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170113596A (cg-RX-API-DMAC10.html)
CN (1) CN107405403B (cg-RX-API-DMAC10.html)
AU (1) AU2015382376B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017016388A2 (cg-RX-API-DMAC10.html)
CA (1) CA2975445A1 (cg-RX-API-DMAC10.html)
ES (1) ES2864767T3 (cg-RX-API-DMAC10.html)
HK (1) HK1247558A1 (cg-RX-API-DMAC10.html)
IL (1) IL253617A0 (cg-RX-API-DMAC10.html)
MX (1) MX2017010277A (cg-RX-API-DMAC10.html)
RU (1) RU2722641C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201706028RA (cg-RX-API-DMAC10.html)
WO (1) WO2016130179A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371772B2 (en) 2001-08-08 2008-05-13 Takeda Pharmaceutical Company Limited Bicyclic compound, production and use thereof
SG11201704837VA (en) 2014-12-23 2017-07-28 Tobira Therapeutics Inc Process of making cenicriviroc and related analogs
BR112018076449A2 (pt) 2016-06-21 2019-04-09 Tobira Therapeutics, Inc. cenicriviroc purificado e intermediários purificados para fazer cenicriviroc
WO2022235440A1 (en) * 2021-04-21 2022-11-10 The United States Government As Represented By The Department Of Veterans Affairs Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2
CN116270633A (zh) * 2023-03-03 2023-06-23 神经肌肉骨骼再生医学中心有限公司 马拉韦罗在制备治疗肌肉退行性疾病的药物中的用途
CN119954974B (zh) * 2025-04-09 2025-07-22 四川康德赛医疗科技有限公司 一种工程化巨噬细胞，其制备方法及抗纤维化的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2249027A (en) * 1990-10-23 1992-04-29 Fujisawa Pharmaceutical Co Use of macrolide compounds for hepatic failure
WO2014186581A1 (en) * 2013-05-15 2014-11-20 Tobira Therapeutics, Inc. Cenicriviroc compositions and methods of making and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371772B2 (en) 2001-08-08 2008-05-13 Takeda Pharmaceutical Company Limited Bicyclic compound, production and use thereof
EP1825866A4 (en) 2004-12-03 2008-03-12 Takeda Pharmaceutical SOLID PREPARATION
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
DK2723360T3 (en) * 2011-06-27 2017-08-28 Univ Pierre Et Marie Curie Paris 6 CCR2 antagonist peptides
JP6263814B2 (ja) * 2013-03-05 2018-01-24 国立大学法人 岡山大学 細胞死抑制剤及び新規化合物
KR101669124B1 (ko) * 2013-07-11 2016-10-25 서울대학교병원 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2249027A (en) * 1990-10-23 1992-04-29 Fujisawa Pharmaceutical Co Use of macrolide compounds for hepatic failure
WO2014186581A1 (en) * 2013-05-15 2014-11-20 Tobira Therapeutics, Inc. Cenicriviroc compositions and methods of making and using the same

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ACUTE LIVER FAILURE STUDY GROUP ET AL, GASTROENTEROLOGY, W.B. SAUNDERS CO, US, vol. 137, no. 3, ISSN 0016-5085, (2009-09-01), pages 856 - 864.e1, (2009-06-12) *
CROWLEY B, "Antibiotic therapy and peritonitis", LANCET, ELSEVIER, AMSTERDAM, NL, 2001, vol. 357, no. 9253, page 396 *
HIROTAKE TOKUYAMA ET AL, INTERNATIONAL IMMUNOLOGY, 2005, pages 1023 - 1034 *
JUNKER A ET AL, "Selective and dual targeting of CCR2 and CCR5 receptors: A current overview", TOPICS IN MEDICINAL CHEMISTRY, SPRINGER, DE, 2014, vol. 14, pages 187 - 242 *
KLIBANOV, 0. M. et al., "Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection", Current Opinion in Investigational Drugs, (2010), vol. 11, no. 8, pages 940 - 950 *
MARK M. MENNING ET AL, "Fumaric Acid Microenvironment Tablet Formulation and Process Development for Crystalline Cenicriviroc Mesylate, a BCS IV Compound", MOLECULAR PHARMACEUTICS, US, 2013, vol. 10, no. 11, pages 4005 - 4015 *
PETER NORMAN, "A dual CCR2/CCR5 chemokine antagonist, BMS-813160? : Evaluation of WO2011046916", EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, vol. 21, no. 12, pages 1919 - 1924 *
S. Friedman, AASLD Liver Learning, (2013-11-04), pages 1 - 2, URL: http://liverlearning.aasld.org/aasld/2013/thelivermeeting/42765/scott.l.friedman.significant.anti-fibrotic.activity.of.cenicriviroc.a.dual.html, (2018-08-15) *
Tobira Therapeutics, URL:http://www.4-traders.com/news/Tobira-Therapeutics-Presents-Data-Supporting-Anti-Fibrotic-Activity-of-Cenicriviroc-in-Liver-Disease--17426775/ *

Also Published As

Publication number Publication date
EP3256124A1 (en) 2017-12-20
RU2017130289A3 (cg-RX-API-DMAC10.html) 2019-04-22
AU2015382376A1 (en) 2017-08-17
MX2017010277A (es) 2017-12-07
RU2017130289A (ru) 2019-03-12
KR20170113596A (ko) 2017-10-12
SG11201706028RA (en) 2017-08-30
ES2864767T3 (es) 2021-10-14
US20200360347A1 (en) 2020-11-19
WO2016130179A1 (en) 2016-08-18
US20190343806A1 (en) 2019-11-14
CN107405403B (zh) 2021-04-20
JP2018505218A (ja) 2018-02-22
CN107405403A (zh) 2017-11-28
JP6676660B2 (ja) 2020-04-08
HK1247558A1 (zh) 2018-09-28
CA2975445A1 (en) 2016-08-18
RU2722641C2 (ru) 2020-06-02
IL253617A0 (en) 2017-09-28
JP2020111586A (ja) 2020-07-27
BR112017016388A2 (pt) 2018-03-27
US20180110754A1 (en) 2018-04-26
EP3256124B1 (en) 2020-12-23
EP3256124A4 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
US20200368247A1 (en) Cenicriviroc for the treatment of fibrosis
AU2015314830B2 (en) Cenicriviroc combination therapy for the treatment of fibrosis
US20200360347A1 (en) Cenicriviroc for the treatment of fibrosis
US20200268768A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
US20230312594A1 (en) PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
JP2022533368A (ja) Ｍｋ２媒介性障害の治療方法
HK40047399A (en) Cenicriviroc combination therapy for the treatment of fibrosis
KR20250090355A (ko) Iga 신병증 치료를 위한 엔도텔린 수용체 길항제 및 글루코코르티코이드의 조합
Heiser Janus Kinase Inhibitors, Abatacept, Rituximab and Tumor Necrosis Factor Inhibitors Efficacy in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee